PURPOSE: The aim of this study was to determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan (CPT-11) plus S-1 in advanced colorectal cancer. METHODS: S-1 was administered orally at 80 mg/m(2) per day for 14 consecutive days followed by a 2-week rest. CPT-11 was given intravenously on days 1 and 15 of each course, at an initial dose of 80 mg/m(2) per day, stepping up to 100, 120 or 150 mg/m(2) per day. Courses were repeated every 4 weeks, unless disease progression or severe toxicities were observed. RESULTS: A total of 21 patients were entered in this study. The maximum tolerated dose of CPT-11 was considered to be 150 mg/m(2), because 2 of 3 patients developed dose-limiting toxicities such as leukopenia, neutropenia, diarrhea and anorexia. The recommend dose of CPT-11 was set at 120 mg/m(2). Tumor response rate was 42.8% and median progression-free survival time was 10 months (95% confidential interval, 6.0-14.0 months). CONCLUSION: A combination of S-1 and CPT-11 showed a good safety profile and can be recommended for further phase II studies in patients with colorectal cancer.
PURPOSE: The aim of this study was to determine the maximum tolerated dose, recommended dose and dose-limiting toxicities of irinotecan (CPT-11) plus S-1 in advanced colorectal cancer. METHODS: S-1 was administered orally at 80 mg/m(2) per day for 14 consecutive days followed by a 2-week rest. CPT-11 was given intravenously on days 1 and 15 of each course, at an initial dose of 80 mg/m(2) per day, stepping up to 100, 120 or 150 mg/m(2) per day. Courses were repeated every 4 weeks, unless disease progression or severe toxicities were observed. RESULTS: A total of 21 patients were entered in this study. The maximum tolerated dose of CPT-11 was considered to be 150 mg/m(2), because 2 of 3 patients developed dose-limiting toxicities such as leukopenia, neutropenia, diarrhea and anorexia. The recommend dose of CPT-11 was set at 120 mg/m(2). Tumor response rate was 42.8% and median progression-free survival time was 10 months (95% confidential interval, 6.0-14.0 months). CONCLUSION: A combination of S-1 and CPT-11 showed a good safety profile and can be recommended for further phase II studies in patients with colorectal cancer.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Emilio Bajetta; Maria Di Bartolomeo; Luigi Mariani; Antonio Cassata; Salvatore Artale; Sergio Frustaci; Graziella Pinotti; Andrea Bonetti; Ignazio Carreca; Guido Biasco; Luigi Bonaglia; Giovanni Marini; Antonio Iannelli; Diego Cortinovis; Ermina Ferrario; Elena Beretta; Antonio Lambiase; Roberto Buzzoni Journal: Cancer Date: 2004-01-15 Impact factor: 6.860
Authors: T Shirasaka; K Nakano; T Takechi; H Satake; J Uchida; A Fujioka; H Saito; H Okabe; K Oyama; S Takeda; N Unemi; M Fukushima Journal: Cancer Res Date: 1996-06-01 Impact factor: 12.701
Authors: P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: H J Mackay; M Hill; C Twelves; R Glasspool; T Price; S Campbell; A Massey; M A Macham; M Uzzel; S M Bailey; C Martin; D Cunningham Journal: Ann Oncol Date: 2003-08 Impact factor: 32.976
Authors: M L Veronese; J P Stevenson; W Sun; M Redlinger; K Algazy; B Giantonio; S Hahn; D Vaughn; C Thorn; A S Whitehead; D G Haller; P J O'Dwyer Journal: Eur J Cancer Date: 2004-03 Impact factor: 9.162
Authors: E Bajetta; M Di Bartolomeo; R Buzzoni; L Mariani; N Zilembo; E Ferrario; S Lo Vullo; E Aitini; L Isa; C Barone; S Jacobelli; E Recaldin; G Pinotti; A Iop Journal: Br J Cancer Date: 2007-01-23 Impact factor: 7.640